glp1
MariTide (maridebart cafraglutide) tracker
Educational reference for MariTide (maridebart cafraglutide). Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
504 h
Tmax
—
Category
glp1
Also known as: maridebart-cafraglutide, amg-133
MariTide is an investigational GIP antagonist and GLP-1 agonist conjugate.
Mechanism
An investigational antibody-peptide conjugate that antagonizes the GIP receptor while activating the GLP-1 receptor.
Research summary
Studied in phase 1 and phase 2 obesity trials with less frequent dosing than weekly agents. Not FDA-approved.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- MariTide phase 1 first-in-human study · Nature Metabolism (per secondary reports)Half-life reported by the sponsor and secondary summaries as about 21 days (~504 h); the primary PK table was not independently verified.
TrackPep là ứng dụng theo dõi. Ứng dụng chỉ ghi lại những gì bạn nhập, không bao giờ đề xuất hay tính toán lượng dùng.